| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.6 | 0.3 |
| Gross profit | 0.4 | 0.1 |
| Net income | -3.6 | -10.9 |
| EPS (diluted, $ a share) | $-0.10 | $-0.34 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +115.0% |
|---|---|
| Gross margin | 75.1% |
10-Q filed with the SEC, NASDAQ: IMDX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Insight Molecular Diagnostics Inc.: key numbers
- Share price
- $1.86Close, Nov 16
- Market cap
- $60.9M
- Shares outstanding
- 32.76MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Insight Molecular Diagnostics Inc.
All →Insight Molecular Diagnostics Financial Results
Insight Molecular Diagnostics reported Q3 2026 financial results, highlighting revenue of $559,000 and progress on its FDA de novo submission for GraftAssureDx. The company also announced the initiation of patient enrollment in its GALACTIC registry study at UCLA Medical Center to support its decentralized testing thesis.
- Term
- Q3 2026
Insight Molecular Diagnostics M&A Deal with Chronix Biomedical, Inc.
Insight Molecular Diagnostics (iMDx) entered into Amendment No. 2 to its merger agreement with Chronix, modifying the earnout structure related to the CNI Monitor technology. The amendment establishes that equity holders will receive a 10% royalty on sales until a potential sale of the technology occurs, at which point they will receive a final payment of 10% of the gross sale proceeds.
- Counterparty
- Chronix Biomedical, Inc.